Return to Listing

1 result(s) for Iclusig

PI Name Protocol # Title
Michael Heinrich STUDY00015085 A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080